Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

AHRQ DES study: "Largest ever real-world study" comparing drug-eluting (DES) and bare metal stents (BMS) demonstrates the former were associated with significantly lower rates of death in Medicare patients undergoing percutaneous coronary intervention, Agency for Healthcare Research and Quality concludes in Feb. 10 research report. The study included 217,675 DES patients and 45,025 BMS patients. At 30 months, unadjusted rates of death were 12.9% for DES and 17.9% for BMS. Rates of myocardial infarction and revascularization were, respectively, 7.3 and 23.0 per 100 patients in the DES group, and 10.0 and 24.5 per 100 patients in the BMS arm. DES patients also had lower rates of adjusted death and MI, with minimal difference in revascularization, stroke or bleeding

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts